 Cynthia Firnhaber
Concepts (274)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Dysplasia | 15 | 2022 | 39 | 6.090 |
Why?
| | Uterine Cervical Neoplasms | 19 | 2022 | 212 | 5.470 |
Why?
| | HIV Infections | 45 | 2022 | 2470 | 4.350 |
Why?
| | Papillomavirus Infections | 17 | 2022 | 258 | 4.160 |
Why?
| | South Africa | 40 | 2021 | 162 | 3.280 |
Why?
| | Papillomaviridae | 11 | 2022 | 100 | 2.660 |
Why?
| | HIV Seropositivity | 8 | 2017 | 110 | 1.710 |
Why?
| | Alphapapillomavirus | 2 | 2022 | 36 | 1.590 |
Why?
| | Papillomavirus Vaccines | 5 | 2021 | 222 | 1.560 |
Why?
| | Early Detection of Cancer | 7 | 2022 | 339 | 1.560 |
Why?
| | Tuberculosis, Multidrug-Resistant | 9 | 2019 | 46 | 1.460 |
Why?
| | Acquired Immunodeficiency Syndrome | 4 | 2022 | 218 | 1.240 |
Why?
| | Antiretroviral Therapy, Highly Active | 7 | 2020 | 256 | 1.210 |
Why?
| | Cryotherapy | 2 | 2017 | 16 | 1.170 |
Why?
| | Rifampin | 9 | 2021 | 68 | 1.140 |
Why?
| | Quality Assurance, Health Care | 5 | 2017 | 314 | 1.130 |
Why?
| | Breast Neoplasms | 4 | 2019 | 1865 | 1.110 |
Why?
| | Colposcopy | 3 | 2015 | 17 | 1.090 |
Why?
| | Papanicolaou Test | 6 | 2018 | 38 | 1.000 |
Why?
| | Antitubercular Agents | 7 | 2021 | 169 | 0.970 |
Why?
| | HIV-1 | 12 | 2020 | 768 | 0.970 |
Why?
| | Optical Imaging | 2 | 2015 | 54 | 0.950 |
Why?
| | Vaginal Smears | 4 | 2022 | 48 | 0.900 |
Why?
| | Anti-HIV Agents | 12 | 2020 | 668 | 0.890 |
Why?
| | Adult | 47 | 2022 | 30710 | 0.810 |
Why?
| | Delayed Diagnosis | 2 | 2019 | 71 | 0.780 |
Why?
| | Molecular Diagnostic Techniques | 3 | 2017 | 91 | 0.740 |
Why?
| | Antibiotics, Antitubercular | 3 | 2019 | 35 | 0.730 |
Why?
| | Female | 58 | 2022 | 59719 | 0.720 |
Why?
| | Cost-Benefit Analysis | 5 | 2018 | 545 | 0.640 |
Why?
| | CD4 Lymphocyte Count | 11 | 2018 | 257 | 0.630 |
Why?
| | Antibodies, Viral | 4 | 2018 | 522 | 0.610 |
Why?
| | Hepatitis B | 2 | 2008 | 53 | 0.610 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2018 | 76 | 0.600 |
Why?
| | Breast | 1 | 2018 | 139 | 0.600 |
Why?
| | Access to Information | 1 | 2018 | 49 | 0.600 |
Why?
| | Contraceptive Agents, Female | 2 | 2020 | 65 | 0.600 |
Why?
| | Prevalence | 13 | 2018 | 2257 | 0.580 |
Why?
| | Oncology Service, Hospital | 1 | 2017 | 14 | 0.570 |
Why?
| | Ambulatory Care Facilities | 2 | 2017 | 211 | 0.560 |
Why?
| | Electrosurgery | 1 | 2017 | 43 | 0.550 |
Why?
| | Anus Neoplasms | 2 | 2015 | 24 | 0.540 |
Why?
| | Humans | 65 | 2022 | 115221 | 0.530 |
Why?
| | Tuberculosis | 5 | 2021 | 241 | 0.520 |
Why?
| | Trichomonas vaginalis | 2 | 2012 | 7 | 0.520 |
Why?
| | Health Resources | 1 | 2017 | 122 | 0.510 |
Why?
| | Surgical Instruments | 1 | 2015 | 48 | 0.510 |
Why?
| | Health Services Accessibility | 2 | 2019 | 770 | 0.500 |
Why?
| | Mobile Health Units | 1 | 2015 | 17 | 0.490 |
Why?
| | Women's Health Services | 1 | 2015 | 15 | 0.490 |
Why?
| | Viral Load | 8 | 2020 | 405 | 0.490 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2015 | 82 | 0.480 |
Why?
| | Middle Aged | 25 | 2019 | 26872 | 0.480 |
Why?
| | Specimen Handling | 1 | 2015 | 155 | 0.470 |
Why?
| | Rural Health Services | 1 | 2015 | 93 | 0.470 |
Why?
| | Precancerous Conditions | 4 | 2020 | 156 | 0.460 |
Why?
| | Urban Population | 3 | 2018 | 402 | 0.460 |
Why?
| | Patient Acceptance of Health Care | 1 | 2019 | 679 | 0.430 |
Why?
| | Anti-Retroviral Agents | 5 | 2021 | 207 | 0.420 |
Why?
| | Genital Neoplasms, Male | 1 | 2012 | 6 | 0.420 |
Why?
| | Mycoplasma genitalium | 1 | 2012 | 2 | 0.420 |
Why?
| | Urethritis | 1 | 2012 | 3 | 0.420 |
Why?
| | Uterine Cervicitis | 1 | 2012 | 7 | 0.410 |
Why?
| | Neisseria gonorrhoeae | 1 | 2012 | 20 | 0.410 |
Why?
| | Chlamydia trachomatis | 1 | 2012 | 36 | 0.410 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2012 | 39 | 0.410 |
Why?
| | HIV | 3 | 2022 | 208 | 0.410 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2016 | 288 | 0.410 |
Why?
| | Hepatitis B Surface Antigens | 2 | 2008 | 19 | 0.400 |
Why?
| | Sensitivity and Specificity | 7 | 2017 | 1717 | 0.390 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2017 | 577 | 0.390 |
Why?
| | Genital Neoplasms, Female | 1 | 2012 | 70 | 0.380 |
Why?
| | Mass Screening | 5 | 2022 | 1011 | 0.380 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2012 | 117 | 0.380 |
Why?
| | Condylomata Acuminata | 1 | 2011 | 6 | 0.380 |
Why?
| | Penile Diseases | 1 | 2011 | 5 | 0.380 |
Why?
| | Protease Inhibitors | 1 | 2011 | 100 | 0.360 |
Why?
| | Coinfection | 5 | 2018 | 120 | 0.360 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2018 | 1190 | 0.350 |
Why?
| | Neutropenia | 1 | 2010 | 126 | 0.350 |
Why?
| | Anemia | 1 | 2010 | 144 | 0.330 |
Why?
| | Cervix Uteri | 2 | 2019 | 44 | 0.320 |
Why?
| | Thrombocytopenia | 1 | 2010 | 178 | 0.320 |
Why?
| | Diarylquinolines | 2 | 2018 | 5 | 0.310 |
Why?
| | Health Care Costs | 4 | 2018 | 381 | 0.300 |
Why?
| | Delivery of Health Care | 1 | 2015 | 836 | 0.300 |
Why?
| | Women's Health | 1 | 2009 | 271 | 0.290 |
Why?
| | Young Adult | 15 | 2018 | 10519 | 0.290 |
Why?
| | Anal Canal | 2 | 2018 | 83 | 0.290 |
Why?
| | Disease Progression | 4 | 2016 | 2390 | 0.280 |
Why?
| | DNA, Viral | 3 | 2018 | 350 | 0.270 |
Why?
| | Antineoplastic Agents | 1 | 2017 | 1882 | 0.260 |
Why?
| | Human Papillomavirus DNA Tests | 2 | 2017 | 3 | 0.260 |
Why?
| | Acetic Acid | 2 | 2016 | 16 | 0.260 |
Why?
| | Atazanavir Sulfate | 2 | 2016 | 41 | 0.260 |
Why?
| | Adolescent | 13 | 2022 | 17889 | 0.250 |
Why?
| | Prospective Studies | 7 | 2019 | 6245 | 0.250 |
Why?
| | Neoplasm Staging | 2 | 2019 | 1171 | 0.250 |
Why?
| | Tenofovir | 2 | 2017 | 204 | 0.240 |
Why?
| | Health Status | 1 | 2009 | 726 | 0.240 |
Why?
| | Developing Countries | 4 | 2018 | 236 | 0.240 |
Why?
| | Medroxyprogesterone Acetate | 2 | 2021 | 28 | 0.240 |
Why?
| | Treatment Outcome | 9 | 2018 | 9151 | 0.230 |
Why?
| | Drug Resistance, Bacterial | 2 | 2016 | 155 | 0.230 |
Why?
| | Laboratories | 2 | 2015 | 95 | 0.230 |
Why?
| | Male | 22 | 2019 | 55813 | 0.220 |
Why?
| | Lamivudine | 2 | 2015 | 59 | 0.220 |
Why?
| | Zidovudine | 2 | 2015 | 77 | 0.220 |
Why?
| | Comorbidity | 3 | 2016 | 1458 | 0.210 |
Why?
| | Retrospective Studies | 8 | 2021 | 12596 | 0.200 |
Why?
| | Vaccination | 3 | 2021 | 1205 | 0.200 |
Why?
| | Aged | 8 | 2019 | 19135 | 0.200 |
Why?
| | Cytochrome P-450 CYP3A Inducers | 1 | 2021 | 5 | 0.190 |
Why?
| | Risk Factors | 7 | 2017 | 8658 | 0.190 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 1 | 2021 | 18 | 0.190 |
Why?
| | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 2 | 2018 | 15 | 0.190 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2021 | 62 | 0.180 |
Why?
| | Human papillomavirus 18 | 2 | 2011 | 14 | 0.180 |
Why?
| | Human papillomavirus 16 | 2 | 2011 | 25 | 0.180 |
Why?
| | Incidence | 4 | 2017 | 2324 | 0.180 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 3 | 2018 | 242 | 0.180 |
Why?
| | Mycobacterium tuberculosis | 3 | 2019 | 268 | 0.180 |
Why?
| | Glycomics | 1 | 2020 | 7 | 0.180 |
Why?
| | Benzoxazines | 2 | 2021 | 28 | 0.170 |
Why?
| | Cyclopropanes | 2 | 2021 | 81 | 0.170 |
Why?
| | Nucleic Acid Amplification Techniques | 2 | 2019 | 34 | 0.170 |
Why?
| | Alkynes | 2 | 2021 | 53 | 0.170 |
Why?
| | Lopinavir | 3 | 2021 | 29 | 0.170 |
Why?
| | Africa | 3 | 2020 | 95 | 0.170 |
Why?
| | Africa, Southern | 2 | 2016 | 8 | 0.170 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2021 | 859 | 0.160 |
Why?
| | Ritonavir | 3 | 2021 | 71 | 0.160 |
Why?
| | Drug Combinations | 2 | 2021 | 287 | 0.160 |
Why?
| | Urban Health Services | 1 | 2019 | 61 | 0.160 |
Why?
| | Brazil | 3 | 2016 | 92 | 0.160 |
Why?
| | South America | 3 | 2016 | 51 | 0.150 |
Why?
| | Anus Diseases | 1 | 2017 | 7 | 0.150 |
Why?
| | Uterus | 1 | 2018 | 192 | 0.150 |
Why?
| | Income | 1 | 2018 | 169 | 0.140 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2012 | 965 | 0.140 |
Why?
| | Herpesvirus 2, Human | 1 | 2017 | 27 | 0.140 |
Why?
| | Health Care Surveys | 1 | 2019 | 538 | 0.140 |
Why?
| | Cross-Sectional Studies | 5 | 2019 | 4419 | 0.140 |
Why?
| | Longitudinal Studies | 2 | 2014 | 2388 | 0.140 |
Why?
| | Cost of Illness | 1 | 2018 | 255 | 0.130 |
Why?
| | Herpes Simplex | 1 | 2017 | 88 | 0.130 |
Why?
| | Sex Factors | 3 | 2018 | 1722 | 0.130 |
Why?
| | Neoplasm Grading | 1 | 2017 | 243 | 0.130 |
Why?
| | Atypical Squamous Cells of the Cervix | 1 | 2016 | 1 | 0.130 |
Why?
| | Tertiary Care Centers | 1 | 2017 | 126 | 0.130 |
Why?
| | Cytisus | 1 | 2015 | 1 | 0.130 |
Why?
| | Mental Status and Dementia Tests | 1 | 2016 | 21 | 0.130 |
Why?
| | Menopause | 1 | 2018 | 271 | 0.130 |
Why?
| | Sputum | 2 | 2016 | 285 | 0.130 |
Why?
| | Staining and Labeling | 1 | 2016 | 135 | 0.130 |
Why?
| | Asia | 2 | 2016 | 53 | 0.120 |
Why?
| | Antibodies, Neutralizing | 2 | 2018 | 221 | 0.120 |
Why?
| | Stavudine | 2 | 2012 | 8 | 0.120 |
Why?
| | Socioeconomic Factors | 1 | 2019 | 1082 | 0.120 |
Why?
| | Clinical Trials as Topic | 2 | 2017 | 937 | 0.120 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2016 | 112 | 0.120 |
Why?
| | Pharmacogenetics | 1 | 2016 | 149 | 0.120 |
Why?
| | Models, Theoretical | 1 | 2018 | 517 | 0.120 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2017 | 179 | 0.120 |
Why?
| | Contraception | 1 | 2016 | 118 | 0.120 |
Why?
| | Costs and Cost Analysis | 1 | 2015 | 197 | 0.120 |
Why?
| | Emtricitabine | 1 | 2015 | 147 | 0.120 |
Why?
| | Gene Expression | 1 | 2019 | 1424 | 0.110 |
Why?
| | Health Services Needs and Demand | 1 | 2016 | 246 | 0.110 |
Why?
| | Markov Chains | 3 | 2018 | 114 | 0.110 |
Why?
| | Bacteriological Techniques | 1 | 2014 | 65 | 0.110 |
Why?
| | RNA, Viral | 2 | 2020 | 567 | 0.110 |
Why?
| | Time Factors | 4 | 2018 | 6157 | 0.110 |
Why?
| | Sexually Transmitted Diseases | 1 | 2015 | 154 | 0.110 |
Why?
| | Trichomonas Vaginitis | 1 | 2012 | 1 | 0.110 |
Why?
| | Age Factors | 3 | 2018 | 2900 | 0.100 |
Why?
| | Follow-Up Studies | 3 | 2017 | 4430 | 0.100 |
Why?
| | Antiprotozoal Agents | 1 | 2012 | 12 | 0.100 |
Why?
| | Metronidazole | 1 | 2012 | 19 | 0.100 |
Why?
| | United States | 6 | 2016 | 12256 | 0.100 |
Why?
| | Virus Shedding | 1 | 2012 | 39 | 0.100 |
Why?
| | Mycobacterium | 1 | 2014 | 103 | 0.100 |
Why?
| | Demography | 1 | 2013 | 261 | 0.100 |
Why?
| | Human papillomavirus 6 | 1 | 2011 | 2 | 0.100 |
Why?
| | Botswana | 1 | 2011 | 7 | 0.100 |
Why?
| | Human papillomavirus 11 | 1 | 2011 | 3 | 0.100 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 676 | 0.100 |
Why?
| | Internationality | 1 | 2012 | 144 | 0.100 |
Why?
| | Antigens, Viral | 1 | 2012 | 176 | 0.100 |
Why?
| | Vaginosis, Bacterial | 1 | 2011 | 12 | 0.100 |
Why?
| | Immunity, Humoral | 1 | 2012 | 112 | 0.100 |
Why?
| | Antiviral Agents | 1 | 2017 | 647 | 0.100 |
Why?
| | Lipid Metabolism | 2 | 2011 | 449 | 0.100 |
Why?
| | Seroepidemiologic Studies | 1 | 2011 | 138 | 0.090 |
Why?
| | Molecular Typing | 1 | 2011 | 18 | 0.090 |
Why?
| | Caribbean Region | 1 | 2010 | 19 | 0.090 |
Why?
| | Americas | 1 | 2010 | 20 | 0.090 |
Why?
| | Prognosis | 3 | 2020 | 3336 | 0.090 |
Why?
| | Sexual Partners | 1 | 2012 | 161 | 0.090 |
Why?
| | Vagina | 1 | 2012 | 147 | 0.090 |
Why?
| | Pregnancy | 3 | 2020 | 5525 | 0.090 |
Why?
| | Health Personnel | 1 | 2016 | 575 | 0.090 |
Why?
| | Delayed-Action Preparations | 2 | 2021 | 159 | 0.090 |
Why?
| | Reflex Sympathetic Dystrophy | 1 | 2009 | 6 | 0.090 |
Why?
| | Autoantigens | 1 | 2012 | 397 | 0.080 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1000 | 0.080 |
Why?
| | Leptin | 1 | 2010 | 212 | 0.080 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2014 | 337 | 0.080 |
Why?
| | Cognition | 1 | 2016 | 982 | 0.080 |
Why?
| | Drug Costs | 2 | 2018 | 91 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 4645 | 0.070 |
Why?
| | Adiposity | 1 | 2011 | 467 | 0.070 |
Why?
| | Genotype | 1 | 2011 | 1781 | 0.060 |
Why?
| | Drug Administration Schedule | 2 | 2021 | 721 | 0.060 |
Why?
| | Reproducibility of Results | 1 | 2013 | 2806 | 0.060 |
Why?
| | Algorithms | 1 | 2012 | 1488 | 0.060 |
Why?
| | Primary Health Care | 1 | 2015 | 1514 | 0.060 |
Why?
| | Cohort Studies | 4 | 2017 | 4917 | 0.060 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 1082 | 0.060 |
Why?
| | Contraceptive Effectiveness | 1 | 2021 | 1 | 0.050 |
Why?
| | Nelfinavir | 1 | 2021 | 8 | 0.050 |
Why?
| | Isoniazid | 1 | 2021 | 52 | 0.050 |
Why?
| | Liver | 1 | 2008 | 1688 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2018 | 1214 | 0.050 |
Why?
| | Reference Standards | 1 | 2020 | 160 | 0.040 |
Why?
| | Drug Interactions | 1 | 2021 | 347 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2020 | 161 | 0.040 |
Why?
| | Risk Assessment | 1 | 2008 | 2981 | 0.040 |
Why?
| | Ethiopia | 1 | 2018 | 34 | 0.040 |
Why?
| | Atrophy | 1 | 2018 | 152 | 0.040 |
Why?
| | Quality-Adjusted Life Years | 1 | 2018 | 101 | 0.040 |
Why?
| | Global Health | 1 | 2020 | 288 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 1 | 2019 | 300 | 0.040 |
Why?
| | Squamous Intraepithelial Lesions of the Cervix | 1 | 2017 | 3 | 0.040 |
Why?
| | Virus Replication | 1 | 2020 | 393 | 0.040 |
Why?
| | Proctoscopy | 1 | 2017 | 6 | 0.040 |
Why?
| | Child | 2 | 2016 | 18468 | 0.040 |
Why?
| | Cytodiagnosis | 1 | 2017 | 29 | 0.040 |
Why?
| | Employment | 1 | 2018 | 139 | 0.040 |
Why?
| | Observational Studies as Topic | 1 | 2017 | 90 | 0.030 |
Why?
| | Seroconversion | 1 | 2017 | 46 | 0.030 |
Why?
| | International Cooperation | 1 | 2017 | 172 | 0.030 |
Why?
| | Immunologic Memory | 1 | 2018 | 313 | 0.030 |
Why?
| | Peru | 1 | 2016 | 55 | 0.030 |
Why?
| | HIV Protease Inhibitors | 1 | 2016 | 64 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2017 | 196 | 0.030 |
Why?
| | Verbal Learning | 1 | 2016 | 63 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2016 | 197 | 0.030 |
Why?
| | DNA, Bacterial | 1 | 2016 | 311 | 0.030 |
Why?
| | Reference Values | 1 | 2016 | 748 | 0.030 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2013 | 57 | 0.030 |
Why?
| | Educational Status | 1 | 2016 | 413 | 0.030 |
Why?
| | Pathology | 1 | 2013 | 20 | 0.030 |
Why?
| | Biopsy | 1 | 2017 | 1050 | 0.030 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2013 | 106 | 0.030 |
Why?
| | Polymorphism, Genetic | 1 | 2016 | 618 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1524 | 0.030 |
Why?
| | Africa South of the Sahara | 1 | 2012 | 36 | 0.030 |
Why?
| | Medication Adherence | 1 | 2017 | 537 | 0.030 |
Why?
| | Withholding Treatment | 1 | 2012 | 69 | 0.030 |
Why?
| | Cognitive Dysfunction | 1 | 2016 | 273 | 0.020 |
Why?
| | Serum | 1 | 2011 | 57 | 0.020 |
Why?
| | Absorptiometry, Photon | 1 | 2011 | 223 | 0.020 |
Why?
| | Body Fat Distribution | 1 | 2010 | 44 | 0.020 |
Why?
| | Biomarkers | 1 | 2020 | 3422 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2012 | 959 | 0.020 |
Why?
| | Prednisone | 1 | 2009 | 233 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2012 | 1042 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2011 | 1084 | 0.020 |
Why?
| | Physical Therapy Modalities | 1 | 2009 | 266 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2009 | 451 | 0.020 |
Why?
| | Glucose | 1 | 2010 | 900 | 0.020 |
Why?
| | Mutation | 1 | 2016 | 3350 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2011 | 3128 | 0.010 |
Why?
|
|
Firnhaber's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|